NY-ESO-1 TCR-engineered T-cells demonstrate durable persistence, clinical activity and tolerability in clinical study in multiple myeloma patients

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, has announced that data from its Phase I/II study of its affinity… Source link